Journal
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
Volume 35, Issue 6, Pages 649-652Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/08923973.2013.837060
Keywords
ADCC; antibody; immunotherapy; MUC1; NK cell
Categories
Ask authors/readers for more resources
MUC1 is an important target for antibodies in passive cancer immunotherapy. Antibodies against mucin glycans or mucin peptide backbone alone may give rise to cross reactivity with normal tissues. Therefore, attempts to identify antibodies against cancer-specific MUC1 glycopeptide epitopes havebeen made. We recently demonstrated that a monoclonal antibody against the immunodominant Tn-MUC1 (GalNAc-alpha-MUC1) antigen induced ADCC in breast cancer cell lines, suggesting the feasibility of targeting combined glycopeptide epitopes in future passive cancer immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available